Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 21.28 percent. This is a 65.38 percent increase over losses of $(0.78) per share from the same period last year.